Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies - Wikidata - wikimedia - TriplyDB

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

http://www.wikidata.org/entity/Q33895804

about

Lost in Translation (LiT): IUPHAR Review 6 Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Human IgG4: a structural perspective Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.Immunogenicity of mAbs in non-human primates during nonclinical safety assessment Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28 Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells.Have we overestimated the benefit of human(ized) antibodies?Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.Intracellular distribution of TM4SF1 and internalization of TM4SF1-antibody complex in vascular endothelial cells.Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.Immunogenicity of therapeutic recombinant immunotoxins.Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis.Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.The yin and yang of immunomodulatory biologics: assessing the delicate balance between benefit and risk.Investigative safety science as a competitive advantage for Pharma.Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.Challenges and approaches for the development of safer immunomodulatory biologics.Understanding the correlation between in vitro and in vivo immunotoxicity tests for nanomedicines.Novel therapeutic options for multiple sclerosis.Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases.Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation.Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13).In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions.The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice.Drug Development of Therapeutic Monoclonal Antibodies.Preclinical Toxicological Study of Release-Active Preparations for Prediction of Their Pharmacological Activity and Side Effects.Maturity-related Variability of the Thymus in Cynomolgus Monkeys (Macaca fasciculata).An antidote approach to reduce risk and broaden utility of antibody-based therapeutics.Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization.The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.Optimization of experimental conditions for functional in vitro characterization of humanized antibodies specific for staphylococcal enterotoxin B.

P2860

Q24289150-6F1A2B8C-53A2-43D8-B3C3-2ACC92067BB0 Q26779221-60D89137-A942-44EA-96B1-8170D304402D Q26779758-FC5C9D24-BE0F-438B-8AFF-38127A446A3D Q30382749-DBF9690A-D929-4E96-864D-0F73D41412D5 Q30390955-AFE3DAE9-428C-4072-8182-2D1CF6EB919E Q33573593-F5B5830B-E66A-4065-B7A6-90CFD39A4359 Q33893235-D510F6BE-21DC-475A-938C-24CA42A55D32 Q34142714-71C3AD1A-F010-4CCA-B614-AA9831EA692E Q35154170-A25E7F2A-5B9F-4936-B4FF-8C3B49A2399A Q35817265-942CCCA4-F08C-417A-9AC1-8DF7E4FE5646 Q36083660-13028EE9-098D-410B-95C3-8A7600F5CEB7 Q36181274-42672600-1A87-4CD3-9D78-C2239DBB334B Q36215626-57622A85-99B0-48F1-9408-B45DA7DF6BA3 Q36593468-F784F1A3-20BC-4951-97EB-7D9ADC834CF9 Q36599623-78FD1D8A-7D07-45B4-83F7-B8F181EC6815 Q37690298-E079CB7E-63B7-4419-AB6D-61BBD9435621 Q37902619-849FB580-F6A6-4913-836F-CC84BC18E023 Q37936540-72679A29-970F-40D9-B956-F503E03E2204 Q37973651-2247AA02-1876-46BD-AAAB-79FFDB2280DE Q38024403-759DE6A5-2348-420A-B037-D0767C3E09E9 Q38093368-DD998B73-FA22-4D71-A131-940926A37199 Q38093772-F6F15792-B52D-4EA6-B0D2-FA3BEA7EAFB4 Q38112504-0F7B72F0-0BE7-4D88-B421-C17AAF50D414 Q38170129-C67EE97C-B74B-4931-9182-28111EA01BB0 Q38202541-DF0BF975-842F-425B-8470-93E236419416 Q38208275-78CAA0B5-8025-449A-8F10-20333EFD5D5E Q38219369-5F384C9C-74C9-44EC-ACD1-75C6D3E1A638 Q38223249-2349C5D3-A27C-4CCB-B9F0-778158C33459 Q38357886-1815BD19-5F72-4243-A0AA-0797AEE5C1D0 Q38575679-321EBB3F-5427-4CEB-9589-28138259F911 Q38591278-CDEC9451-22F3-4D32-BEB3-6872C175DB3C Q38765564-CCAB918D-002A-4355-8F52-C090DE9D014F Q38811689-A4D0314C-CF4E-4479-A4C0-0DE1837B26D5 Q38876360-9FE3A2FF-FA7D-4A28-AFD0-79492BA195B4 Q39627907-5474552C-24DE-471B-B5F4-2EF030A4639A Q39735632-EB3119CD-1973-4180-8055-4F8AC2BC06A6 Q40309222-AEEF28F1-CE77-4882-A92C-87BF182B9A8F Q40514614-65EF5180-FDC2-4DE9-843F-1F77C3615F54 Q40748706-527DEDC9-3578-4AA1-8A6D-B5CD557347D6 Q41129982-881002ED-897A-4174-A2EB-D84C5C3CC6D9

P2860

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

http://www.wikidata.org/entity/Q33895804

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@ast

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@en

type

label

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@ast

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@en

prefLabel

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@ast

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@en

P1433

Q33895804-5384F01C-1517-47A0-99A6-7F8D1D927CA4

P1476

Q33895804-24F0A715-32F6-4372-939C-B77927D7B418

P2093

Q33895804-138B1F23-336E-4F98-86C0-DE0E606F23F7

Q33895804-1925EB9B-5CBA-4358-8CF7-70C536706AFC

Q33895804-329BD423-69EA-47FB-B71E-C2DBD2A6334F

Q33895804-33624203-C386-46A4-81CE-0FA963A27DD9

Q33895804-5298FF02-CB18-440F-B865-4840DA02C3AF

Q33895804-5DE21EC2-A1AE-4096-A6A7-3F1DCDE8FAF1

Q33895804-69617908-1AD3-414E-8DBA-3C1186949D48

Q33895804-93F246A8-A27F-48AA-8CAE-E5E0C4543DAF

Q33895804-959809B2-D72D-47C9-AB91-AEBBCE9EABB2

P2860

Q33895804-01C651A2-40E9-424E-B0C7-F3EE0B045309

Q33895804-0394C7DC-6987-4B59-BDC4-F34B589F2388

Q33895804-05341DD1-F0FD-4D07-A133-2D19E9FEE0C2

Q33895804-055C672E-9C14-4710-83BF-7258DAAB30C1

Q33895804-06984B77-3D16-4D3E-ACC7-F5B0D161CE3E

Q33895804-0AFC76E0-F1B1-4BD1-9D00-C8A496F0FDF6

Q33895804-0B69CF47-78EF-40AB-9000-AC41A04FE1CD

Q33895804-0C8D36B4-B359-49F8-A741-B3BDC8B31BC6

Q33895804-10405229-C312-4CD6-9752-0FA9102BB9ED

Q33895804-10A81819-607F-4D72-8E52-3E43D94CF6A2

P304

Q33895804-F2F5E95A-40AF-4C1B-81FF-163AE68390D1

P31

Q33895804-DD7E40D4-F1B7-420B-8402-1175398E4FE3

P356

Q33895804-26E9016E-ED0C-415F-89E1-DA2CDD1921ED

P433

Q33895804-8788EA05-232F-4F47-AD10-9528BE5FDE30

P478

Q33895804-464CDA20-3B57-4C20-9DD8-FE0A85C96E1F

P577

Q33895804-7C75F01C-588D-4455-B180-3DC524ED58C1

P698

Q33895804-A2E7B5B4-822C-427D-8EC6-C6029B7AAA40

P921

Q33895804-F02B56D6-32A9-4334-B842-41F676851AD0

P932

Q33895804-486AE30C-EEE7-448A-9DEB-99A10146BEA1

P356

P1433

Monoclonal Antibodies

P1476

Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies

@en

P2093

Adam Hey

http://www.w3.org/2001/XMLSchema#string

Andrea Kiessling

http://www.w3.org/2001/XMLSchema#string

Frank R Brennan

http://www.w3.org/2001/XMLSchema#string

Jennifer Sims

http://www.w3.org/2001/XMLSchema#string

Laura Dill Morton

http://www.w3.org/2001/XMLSchema#string

Patrick Y Muller

http://www.w3.org/2001/XMLSchema#string

Roy Allenspach

http://www.w3.org/2001/XMLSchema#string

Sebastian Spindeldreher

http://www.w3.org/2001/XMLSchema#string

Werner Frings

http://www.w3.org/2001/XMLSchema#string

P2860

The accuracy of extended histopathology to detect immunotoxic chemicals

Immunotoxicity of monoclonal antibodies

Preclinical development of monoclonal antibodies: considerations for the use of non-human primates

Forecasting the cytokine storm following systemic interleukin (IL)-2 administration

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method.

Structural characterization of a human Fc fragment engineered for lack of effector functions

Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

Fcgamma receptors as regulators of immune responses

P304

233-255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.2.3.11782

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20421713

http://www.w3.org/2001/XMLSchema#string

P921

P932

2881251

http://www.w3.org/2001/XMLSchema#string